Sonnet Biotherapeutics Holdings Inc
$ 1.26
-59.35%
02 Dec - close price
- Market Cap 8,602,500 USD
- Current Price $ 1.26
- High / Low $ 3.23 / 1.26
- Stock P/E N/A
- Book Value -0.91
- EPS -6.82
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -2.24 %
- ROE -7.15 %
- 52 Week High 10.38
- 52 Week Low 1.08
About
Sonnet BioTherapeutics Holdings, Inc., an oncology-focused biotech company, develops a platform for single-acting or bispecific biologics. The company is headquartered in Princeton, New Jersey.
Analyst Target Price
$20.00
Quarterly Earnings
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-08-13 | 2025-05-12 | 2025-02-12 | 2024-12-12 | 2024-08-14 | 2024-05-14 | 2024-02-14 | 2023-12-14 | 2023-08-14 | 2023-05-10 | 2023-02-13 | 2022-12-15 |
| Reported EPS | -0.95 | -0.89 | -1.56 | -10.39 | -0.7 | 0.07 | -0.31 | -2.09 | -0.13 | -0.34 | -0.8 | -1.67 |
| Estimated EPS | -0.49 | -0.92 | -11.12 | -5.52 | -0.76 | 0.14 | -0.9 | -4.09 | -0.31 | -0.49 | -1.1 | -1.51 |
| Surprise | -0.46 | 0.03 | 9.56 | -4.87 | 0.06 | -0.07 | 0.59 | 2 | 0.18 | 0.15 | 0.3 | -0.16 |
| Surprise Percentage | -93.8776% | 3.2609% | 85.9712% | -88.2246% | 7.8947% | -50% | 65.5556% | 48.8998% | 58.0645% | 30.6122% | 27.2727% | -10.596% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SONN
2026-01-10 00:28:44
The article reports that Sonnet BioTherapeutics (SONN) stock surged by 82% following a licensing deal with Rorschach I, a Japanese biotech company. This significant jump is attributed to retail investor enthusiasm. The deal involves Sonnet's interleukin-12 variant, SON-1010, which will be developed for various cancer indications.
2025-12-09 22:08:26
Lowenstein Sandler represented Sonnet BioTherapeutics Holdings (NASDAQ: SONN) in the successful closing of its business combination with Hyperliquid Strategies. Following the transaction, Hyperliquid will operate as a HYPE digital asset treasury reserve company, with Sonnet as its wholly-owned subsidiary, and Hyperliquid's common stock now trades on Nasdaq under "PURR" since December 3, 2025. This merger is expected to create the largest U.S.-based publicly listed company holding approximately 12.6 million HYPE tokens, valued at $583 million.
2025-12-06 19:08:49
Hyperliquid Strategies (HSI) has completed its business combination with Sonnet BioTherapeutics and Rorschach I LLC, with HSI common stock expected to begin trading on The Nasdaq Capital Market under the ticker "PURR" on December 3, 2025. Sonnet will operate as a wholly-owned subsidiary, and its common stock will cease trading. The deal, which involved a five-for-one share exchange ratio, establishes HSI as a digital asset treasury reserve company focused on the HYPE token.
2025-12-04 21:09:53
Sonnet BioTherapeutics Holdings, Inc. shareholders have approved a proposed business combination with Hyperliquid Strategies Inc (HSI) and Rorschach I LLC. The final voting results will be submitted to the U.S. Securities and Exchange Commission (SEC) on Form 8-K. Upon completion of the transaction, HSI's securities are expected to be listed on Nasdaq.
2025-12-03 18:09:37
Sonnet BioTherapeutics Holdings (SONN) announced its merger with Hyperliquid Strategies Inc (HSI) and Rorschach I LLC on December 2, 2025. This strategic move transforms HSI into a digital asset treasury reserve company, trading on Nasdaq under 'PURR' and providing U.S. equity investors access to the HYPE token. An analyst currently rates SONN stock as a Sell with a $4.00 price target. This merger positions the combined entity to leverage the growing digital asset market while Sonnet's historical financial performance indicates significant risks.
2025-12-03 05:10:07
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) announced that its stockholders have approved a business combination with Hyperliquid Strategies Inc (HSI) and Rorschach I LLC. This micro-cap biotech, currently valued at $21.16 million, uses a proprietary FHAB platform for oncology-focused treatments. The securities of HSI are expected to be listed on Nasdaq upon completion of the merger.
